Dianthus Therapeutics slips after starting $400 mln stock sale

Jefferies Financial

09/03/2026 20:23

** Dianthus Therapeutics DNTH.O shares down 5% to $75.26 post-market after announcing planned equity raise

** Co commences $400 mln stock offering to advance clinical and preclinical development activities, commercial readiness activities and for other purposes

** DNTH shares jumped 21.5% to close at $79.23 on Mon after its nerve disease drug showed faster‑than‑expected response in late-stage trial

** Jefferies, TD Cowen, Evercore, Stifel, Guggenheim and William Blair joint bookrunners for stock offering

** New York City-based DNTH has ~44.5 mln shares outstanding for about $3.5 bln market cap

** Stock up 92% YTD as of the close

** All 15 analysts are bullish on the stock including 7 "strong buy" ratings; median PT of $105.50 up from $66 a month ago, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))